# Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

> **NCT01685801** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 24 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ivacaftor
- **DRUG:** Placebo-matched-to-ivacaftor tablet

## Key facts

- **NCT ID:** NCT01685801
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685801, "Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01685801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*